Copyright
©The Author(s) 2022.
World J Gastrointest Pharmacol Ther. Jul 5, 2022; 13(4): 47-56
Published online Jul 5, 2022. doi: 10.4292/wjgpt.v13.i4.47
Published online Jul 5, 2022. doi: 10.4292/wjgpt.v13.i4.47
Table 2 Comparison between primary hyperparathyroidism without pancreatitis and primary hyperparathyroidism with acute pancreatitis
| Parameters | PHPT-NP, n = 39 | PHPT-AP, n = 05 | P value |
| Age (yr) | 49.23 ± 14.80 | 35.20 ± 16.11 | 0.05 |
| Female gender | 27 (69.23%) | 0 | |
| Bone pain | 22 (56.41%) | 1 (20%) | 0.17 |
| Fracture | 04 (10.26%) | 0 | |
| Pain abdomen | 10 (25.64%) | 5 (100%) | < 0.01 |
| Nausea and vomiting | 05 (12.82%) | 5 (100%) | < 0.01 |
| Weight loss | 06 (15.38%) | 1 (20%) | 1 |
| Fatigue and weakness | 18 (46.15%) | 2 (40%) | 1 |
| Anorexia | 06(15.38%) | 4 (80%) | < 0.01 |
| Psychiatric features | 03 (7.69%) | 0 | |
| Nephrolithiasis | 14 (35.89%) | 0 | |
| Nephrocalcinosis | 09 (23.07%) | 0 | |
| Cholelithiasis | 02 (5.12%) | 1 (20%) | 0.31 |
| Serum creatinine(mg/dL) | 0.80 (0.60-1.19) | 0.74 (0.66-0.89) | 0.66 |
| Serum corrected calcium(mg/dL) | 12.46 ± 1.71 | 11.66 ± 1.15 | 0.32 |
| Serum phosphorous (mg/dL) | 2.7 (2.2-3.17) | 2.7 (2.02-2.90) | 0.62 |
| Serum magnesium (mg/dL) | 1.82 ± 0.33 | 1.76 ± 0.34 | 0.72 |
| Serum albumin (g/dL) | 3.90 (3.5-4.1) | 4.2 (3.7-4.75) | 0.18 |
| Serum ALP (IU/L) | 242 (148-764.5) | 112 (106.25-147) | 0.03 |
| Serum 25-OH vitamin D(ng/mL) | 15.48 (10.24-21.37) | 25.91 (13.88-31.72) | 0.33 |
| Plasma iPTH (pg/mL) | 519.80(149-1649.55) | 125 (80.55-178.65) | 0.01 |
- Citation: Rashmi KG, Kamalanathan S, Sahoo J, Naik D, Mohan P, Pottakkat B, Kar SS, Palui R, Roy A. Primary hyperparathyroidism presenting as acute pancreatitis: An institutional experience with review of the literature. World J Gastrointest Pharmacol Ther 2022; 13(4): 47-56
- URL: https://www.wjgnet.com/2150-5349/full/v13/i4/47.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v13.i4.47